Targeting Nrf2 Antioxidant Defences Could Help Overcome Colorectal Cancer Drug Resistance, Review Finds

Nrf2 antioxidant defences, Digimart Global: A new review published in Genes & Diseases highlights a possible weak point in colorectal cancer: the antioxidant defences that help tumour cells survive treatment. The article, prepared by a team at China Medical University and affiliated hospitals, examines how adjusting the activity of Nrf2, a regulator of these defences, could help trigger cell death pathways and address drug resistance.

Nrf2 plays a double-edged role. It protects healthy intestinal cells from oxidative damage, but when it stays persistently active in cancer cells, it can strengthen their defences and reduce their sensitivity to chemotherapy.

This makes the pathway a promising but challenging therapeutic target, according to the review.

The article focuses on reactive oxygen species, reactive molecules produced during normal cell activity. Cancer cells operate under heightened oxidative stress and rely on protective systems to keep these molecules within tolerable limits.

Disrupting that balance may push tumour cells towards death, although healthy tissues also need protection.

The review centres on three interconnected processes: apoptosis, the controlled breakdown of cells; ferroptosis, an iron-dependent form of cell death driven by damage to membrane fats; and autophagy, the cell recycling system that can support survival or contribute to cell death depending on circumstances. Nrf2 influences these processes by regulating antioxidant production, iron handling and stress responses.

In particular, it can suppress ferroptosis by reinforcing defences against lipid damage, so inhibiting it could make some colorectal cancer cells more vulnerable to treatments designed to trigger ferroptosis or increase oxidative stress.

The authors stress that switching Nrf2 off is not a universal solution. Under certain conditions, activating the pathway can contribute to anticancer effects or protect normal intestinal tissue during treatment, so effective strategies depend on the biological context, the medicine involved and the cells being targeted.

Suggested approaches include combining Nrf2 modulators with chemotherapy, radiotherapy or agents that promote cell death, along with tumour-targeted delivery systems such as nanoparticles to concentrate treatment within cancer tissue.

The review also highlights biomarkers, including Nrf2 pathway activity and related genetic features, as a way to identify patients most likely to benefit. Interactions with immune cells and other supporting cells around tumours add further complexity.

The findings describe a research direction rather than a clinical treatment, and further work would be needed to establish safety and effectiveness.

Callum Fletcher

Callum Fletcher covers international news, Australian sports, entertainment, and cultural developments. His reporting focuses on major global events and trending stories relevant to audiences throughout Australia.
Copy Profile

Leave a Reply

Your email address will not be published. Required fields are marked *

Sports

Explore Digimart Global